Bridgebio Pharma, Inc. · NASDAQ:BBIO
Viking Global Investors LP reported a 6.80% stake in Bridgebio Pharma, Inc. (Schedule 13D/A)
Event Feb 12, 2026 · Filed Feb 17, 2026
Viking Global Investors LP reported a 6.80% stake in Bridgebio Pharma, Inc., 13,026,367 shares, with active intent on Feb 12, 2026. Filed Feb 17, 2026 (Schedule 13D/A).
- Stake
- 6.80%
- Shares
- 13,026,367
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 8 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| VIKING GLOBAL INVESTORS LP | 6.80% | 13,026,367 |
| Viking Global Opportunities Parent GP LLC | 6.80% | 13,026,367 |
| Viking Global Opportunities GP LLC | 6.80% | 13,026,367 |
| Viking Global Opportunities Portfolio GP LLC | 6.80% | 13,026,367 |
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 6.80% | 13,026,367 |
| HALVORSEN OLE ANDREAS | 6.80% | 13,026,367 |
| Ott David C. | 6.80% | 13,026,367 |
| Shabet Rose Sharon | 6.80% | 13,026,367 |
Source
Related
- Bridgebio Pharma, Inc.
- Viking Global Investors LP
- Bridgebio Pharma, Inc. shareholders
- Schedule 13D/A · Viking Global Investors LP · Jul 10, 2026
- Schedule 13D/A · Viking Global Investors LP · Apr 2, 2026
- Schedule 13D/A · Viking Global Investors LP · Nov 14, 2025
- Schedule 13D/A · Viking Global Investors LP · Jul 1, 2025
- Schedule 13D/A · Viking Global Investors LP · Mar 12, 2025
- Form 4 · Kumar Neil · Sep 21, 2026
- Form 4 · Kumar Neil · Aug 20, 2026
- Form 4 · Kumar Neil · Aug 18, 2026
- Form 4 · Trimarchi Thomas · Aug 18, 2026
- Form 4 · Apuli Maricel · Aug 18, 2026